By-health(SZ:300146) Huachuang Securities·2025-10-31 04:19Investment Rating - The investment rating for the company is "Neutral" [1] Core Views - The company reported a revenue of 4.915 billion yuan for the first three quarters of 2025, a year-on-year decrease of 14.27%, while the net profit attributable to shareholders was 907 million yuan, an increase of 4.45% year-on-year [1] - In Q3 alone, the company achieved a revenue of 1.383 billion yuan, a year-on-year increase of 23.45%, and a net profit of 171 million yuan, compared to a loss of 22 million yuan in the same period last year [1] - The company has successfully turned a profit in Q3 due to improved gross margin and optimized expense ratios, with a gross margin of 68.56%, up 3.25 percentage points year-on-year [5] - The company is expected to continue its revenue growth into Q4, aiming for a single-digit decline in revenue for the year [5] - The report emphasizes the importance of new product launches and channel management for future growth [5] Financial Summary - For 2024A, total revenue is projected at 6.838 billion yuan, with a year-on-year growth rate of -27.3% [1] - The net profit for 2024A is estimated at 653 million yuan, with a year-on-year growth rate of -62.6% [1] - The earnings per share (EPS) for 2024A is projected to be 0.39 yuan, with a price-to-earnings (P/E) ratio of 33 [1] - The company’s total assets are expected to be 14.28 billion yuan in 2024A, with a debt-to-equity ratio of 15.7% [11]